Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.48 |
| ▸ | USP10 | Q14694 | 1/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.48 |
| ▸ | USP13 | Q92995 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932470 | 0.89 | EGFR (0.59) | NPC1RAB9AEGFRKMT2ATDP1 | |
| SCHEMBL4065012 | 0.88 | TYK2 (0.66) | TYK2NPC1RAB9AEGFRHTT | |
| SCHEMBL4072924 | 0.87 | CLK4 (0.57) | NPC1RAB9AEGFRKMT2ATDP1 | |
| SCHEMBL4071062 | 0.85 | TYK2 (0.62) | TYK2NPC1RAB9AEGFRKMT2A | |
| SCHEMBL4066517 | 0.85 | CLK4 (0.52) | NPC1RAB9AEGFRKMT2ATDP1 | |
| SCHEMBL4067913 | 0.84 | MAP3K8 (0.52) | TYK2NPC1RAB9AEGFRKMT2A | |
| SCHEMBL4071070 | 0.84 | EGFR (0.50) | NPC1RAB9AEGFRKMT2ATDP1 | |
| SCHEMBL4064454 | 0.82 | PDE5A (0.65) | EGFRKMT2AMEN1CLK4LMNA | |
| SCHEMBL13961313 | 0.82 | NPC1 (0.62) | TYK2NPC1RAB9AEGFRHTT | |
| SCHEMBL4072750 | 0.80 | EGFR (0.56) | NPC1RAB9AEGFRKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| WO-2009007422-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | TYK2 1012/4885NPC1 3333/4885RAB9A 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.